Liglimet 2.5/500 Tablet

About Liglimet 2.5/500 Tablet

Liglimet 2.5/500 is a tablet for adults with type 2 diabetes, combining linagliptin and metformin to help control blood sugar when diet and exercise alone are not enough.

There are 31 brands of Linagliptin + Metformin Hydrochloride listed in Bangladesh. The lowest listed price is Linatin M 2.5 mg + 500 mg Tablet at ৳ 7.00 per unit.

What is Liglimet 2.5/500 Tablet?

Liglimet 2.5/500 is an oral medicine for adults with type 2 diabetes. It contains linagliptin and metformin hydrochloride in a single tablet. Doctors prescribe it alongside diet and exercise when using both ingredients together is appropriate. Linagliptin works by increasing certain gut hormones that help release insulin when blood sugar is high. Metformin is a biguanide that helps lower blood sugar. This combination is not for everyone; a doctor will decide if it suits your situation. The dose and course are set by your doctor based on your needs.

Uses of Liglimet 2.5/500

Liglimet 2.5/500 is used in adults with type 2 diabetes mellitus. It is added to a proper diet and exercise plan to improve blood sugar control when treatment with both linagliptin and metformin is considered appropriate. It is not a replacement for lifestyle measures. Your doctor will assess whether this combination is right for you.

How to use Liglimet 2.5/500

Take Liglimet 2.5/500 exactly as your doctor prescribes. The dose and how often you take it are decided by your doctor, who may adjust them over time based on how well your blood sugar is controlled and how you tolerate the medicine. Swallow the tablet with meals as directed. Do not change the dose yourself. If you miss a dose, ask your doctor or pharmacist what to do.

Side effects of Liglimet 2.5/500

Common side effects include nasopharyngitis (cold-like symptoms) and diarrhoea. Low blood sugar (hypoglycemia) is more common when this medicine is used with sulfonylureas. Contact your doctor promptly if you have severe or persistent diarrhoea, signs of low blood sugar, or any unusual symptoms. Seek immediate medical help if you suspect pancreatitis, such as severe stomach pain.

Safety and precautions

Liglimet 2.5/500 is not suitable for people with kidney problems, metabolic acidosis (including diabetic ketoacidosis), or allergy to linagliptin or metformin. It should be used in pregnancy only if clearly needed, and caution is advised during breastfeeding. Tell your doctor if you have kidney, liver, or heart problems, or if you are scheduled for surgery or a scan with contrast dye. Your doctor may stop the medicine temporarily in these situations. Do not start or stop this medicine without medical advice.

Frequently asked questions

What is Liglimet 2.5/500 used for and what kind of medicine is it?

It is a combination oral medicine for adults with type 2 diabetes. It contains linagliptin and metformin hydrochloride and is used alongside diet and exercise to improve blood sugar control when both ingredients are appropriate. Your doctor will decide if it is right for you.

What side effects should I watch for and when should I call the doctor?

Watch for cold-like symptoms, diarrhoea, or signs of low blood sugar such as shakiness or sweating, especially if you also take a sulfonylurea. Call your doctor if these are severe or persistent, or if you have severe stomach pain that could suggest pancreatitis.

How should I take Liglimet 2.5/500?

Take it exactly as your doctor tells you. The dose and frequency are chosen by your doctor and may be adjusted over time. Swallow the tablet with meals as directed. Do not change the dose yourself, and ask your doctor or pharmacist if you are unsure.

Who should not take Liglimet 2.5/500?

It is not for people with kidney problems, metabolic acidosis such as diabetic ketoacidosis, or allergy to its ingredients. Tell your doctor if you are pregnant or breastfeeding, or if you have surgery or a contrast scan planned, as the medicine may need to be stopped temporarily.

Indications

This is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Linagliptin and Metformin Hydrochloride is appropriate

Pharmacology

Linagliptin is indicated to improve glycemic control in patients with type 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4), an enzyme that degrades the incretin hormones GLP-1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide). Thus, Linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin from pancreatic beta (β) cells in a glucose-dependent manner and decreasing the secretion of glucagon from pancreatic alpha (α) cells in the circulation.

Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin Hydrochloride decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.

Dosage & Administration

Linagliptin & Metformin immediate release tablet: The dosage of Linagliptin & Metformin should be individualized on the basis of both effectiveness and tolerability. Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with Metformin Hydrochloride use.

Recommended starting dose: In patients currently not treated with Metformin Hydrochloride, initiate treatment with 2.5 mg Linagliptin and 500 mg Metformin Hydrochloride twice daily.

In patients already treated with Metformin Hydrochloride, start with 2.5 mg Linagliptin and the current dose of Metformin Hydrochloride twice daily.

Patients already treated with Linagliptin and Metformin Hydrochloride, individual components may be switched to this combination containing the same doses of each component.

Linagliptin & Metformin extend release tablet: The dosage of this combination should be individualized on the basis of both effectiveness and tolerability, while not exceeding the maximum recommended total daily dose of Linagliptin 5 mg and Metformin Hydrochloride 2000 mg. this combination should be given once daily with a meal.

Recommended starting dose: In patients currently not treated with metformin, initiate this combination treatment with 5 mg Linagliptin/1000 mg Metformin Hydrochloride extended-release once daily with a meal.

In patients already treated with Metformin, start this combination with 5 mg of Linagliptin total daily dose and a similar total daily dose of Metformin once daily with a meal.

In patients already treated with Linagliptin & Metformin immediate release tablet, switch to extend release tablet containing 5 mg of Linagliptin total daily dose and a similar total daily dose of Metformin once daily with a meal.

5 mg Linagliptin & 1000 mg Metformin Hydrochloride extended-release tablet should be taken as a single tablet once daily. Patients using 2.5 mg Linagliptin & 1000 mg Metformin extended release tablets should take two tablets together once daily.

Interaction

Cationic drugs (amiloride, digoxin, morphine, ranitidine, trimethoprim etc.): May reduce metformin elimination.

P-glycoprotien/CYP3A4 inducer (i.e. rifampin)
: The efficacy of this medicine may be reduced when administered in combination.

Contraindications

Although Linagliptin undergoes minimal renal excretion, Metformin Hydrochloride is known to be substantially excreted by the kidney. The risk of Metformin Hydrochloride accumulation and lactic acidosis increases with the degree of renal impairment. Therefore, this combination is contraindicated in patients with renal impairment. It is also contraindicated in acute or chronic metabolic acidosis (diabetic ketoacidosis) and in hypersensitivity to Linagliptin or Metformin Hydrochloride.

Side Effects

Most common side effects are nasopharyngitis and diarrhea. Hypoglycemia is more common in patients treated with this combination and sulfonylureas.

Pregnancy & Lactation

There are no adequate and well-controlled studies in pregnant women with this combination or its individual component; so it should be used during pregnancy only if clearly needed. Caution should also be excercised when it is administered to a lactating mother.

Precautions & Warnings

In a patient with lactic acidosis who is taking Metformin, the drug should be discontinued immediately and supportive therapy promptly instituted. There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue Linagliptin & Metformin. Temporarily discontinue Linagliptin & Metformin in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. Metformin may lower Vitamin B12 levels; so hematologic parameters shoud be monitored annually.

Overdose Effects

In the event of an overdose with this combination the usual supportive measures (i.e. remove unabsorbed material from the gastrointestinal tract, perform clinical monitoring, and institute supportive treatment) should be employed. Removal of Linagliptin by hemodialysis or peritoneal dialysis is unlikely but Metformin Hydrochloride is dialyzable.

During controlled clinical trials in healthy subjects, with single doses of up to 600 mg of Linagliptin (equivalent to 120 times the recommended daily dose), there were no dose-related clinical adverse drug reactions.

Overdose of Metformin Hydrochloride has occurred in case of ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with Metformin Hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of Metformin Hydrochloride overdose cases.

Storage Conditions

Keep in a cool & dry place (below 30°C), protected from light & moisture. Keep out of the reach of children.

Alternative brands of Linagliptin + Metformin Hydrochloride

Other brands with the same generic name, cheapest first.

See all 31 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.